Emil Kakkis, President & CEO, Director at Ultragenyx Pharmaceutical, holds 2.83M shares in Ultragenyx Pharmaceutical (Ticker: RARE), holds 44.27K shares in BioMarin Pharmaceutical (Ticker: BMRN).

See the Hottest Stocks Based on Insider Trading >

Emil Kakkis
Ultragenyx Pharmaceutical (RARE)
President & CEO, Director

Ranked #3,171 out of 98,624 Corporate Insiders

Profitable Transactions

4 out of 4 Profitable Transactions

Average Return

+121.90%

Average return per transaction

Time Frame

1 Year

Compare to

No Benchmark

How are Insiders Ranked?

Insider Holdings

97.11%

RARE

2.89%

BMRN

A breakdown of Emil Kakkis's holdings

See the Top Stocks by Insiders

Insider Roles

Ultragenyx Pharmaceutical
(RARE)

President & CEO, Director

BioMarin Pharmaceutical
(BMRN)

CMO

Roles that Emil Kakkis holds in companies

See the Top Corporate Insiders

Most Profitable Insider Trade

Stock:

Ultragenyx Pharmaceutical
(RARE)

Rating:Informative Buy

Date:Mar 13, 2020 - Mar 13, 2021

Return:+192.90%

The most profitable trade made by Emil Kakkis

See the Latest Stocks Traded by Insiders

Emil Kakkis's Trading History

RARE

Ultragenyx Pharmaceutical

Mar 05, 2024

President & CEO, Director

Uninformative Buy

―

$120.30M

BMRN

BioMarin Pharmaceutical

Mar 04, 2009

CMO

Uninformative Sell

92.39K

$3.58M

List of latest transactions for each holding click on a transaction to see Emil Kakkis's performance on stock

See All Insider Trading from Today

Emil Kakkis insider profile FAQ

What is the percentage of profitable transactions made by Emil Kakkis?

The percentage of profitable transactions made by Emil Kakkis is 100%.

What is the average return per transaction made by Emil Kakkis?

The average return per transaction made by Emil Kakkis is 121.90%.

What stocks does Emil Kakkis hold?

Emil Kakkis holds: RARE, BMRN stocks.

What was Emil Kakkis’s latest transaction?

Emil Kakkis latest transaction was an Uninformative Buy of ―.

What was Emil Kakkis's most profitable transaction?

Emil Kakkis’s most profitable transaction was an Informative Buy of RARE stock on March 13, 2020. The return on the trade was 192.90%.

What is Emil Kakkis's role in Ultragenyx Pharmaceutical?

Emil Kakkis's role in Ultragenyx Pharmaceutical is President & CEO, Director.

How can I follow the stock ratings of top corporate insiders?

Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.

Emil Kakkis Insider Profile

Emil Kakkis Ultragenyx Pharmaceutical (RARE)President & CEO, Director